

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	10/501,67/	
Source:	· PG110	
Date Processed by STIC:	7/23/04	
•		

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S.-PATENT AND.

TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
 U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby Room 1B03, Arlington, VA 22202

Revised 05/17/04

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 10/50/,67/
ATTN: NEW RULES CASES:	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
IWrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
Misaligned Amino -Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
Patentin 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13 Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid

ngane i walkali ji i ji ega

AMC - Biotechnology Systems Branch - 09/09/2003



PCT

RAW SEQUENCE LISTING DATE: 07/23/2004
PATENT APPLICATION: US/10/501,671 TIME: 15:23:45

4 <120> TITLE OF INVENTION: High-concentration preparation of soluble thrombomodulin

Input Set : A:\PTO.FG.txt

3 <110> APPLICANT: Asahi Kasei Kabushiki Kaisha

C--> 8 <140> CURRENT APPLICATION NUMBER: US/10/501,671

6 <130> FILE REFERENCE: ASAHI-33

C--> 8 <141> CURRENT FILING DATE: 2004-07-16

Output Set: N:\CRF4\07232004\J501671.raw

```
8 <150> PRIOR APPLICATION NUMBER: JP2002-009951
     9 <151> PRIOR FILING DATE: 2002-01-18
     11 <160> NUMBER OF SEQ ID NOS: 9
                                                              Does Not Comply
ERRORED SEQUENCES
                                                         Corrected Diskette Needec
    13 <210> SEQ ID NO: 1
    14 <211> LENGTH: 516
    15 <212> TYPE: PRT
    16 <213> ORGANISM: Artificial sequence
    18 <220> FEATURE:
    19 <223> OTHER INFORMATION: Partial amino acid sequence of human-originated soluble
             thrombomodulin
    22 <400> SEQUENCE: 1
    23 Met Leu Gly Val Leu Val Leu Gly Ala Leu Ala Leu Ala Gly Leu Gly
                                     10
25 Phe Pro Ala Pro Ala Glu Pro Gln Pro Gly Gly Ser Gln Cys Val Glu E--> 26 20 25 30
    27 His Asp Cys, Phe Ala Leu Tyr Pro Gly Pro Ala Thr Phe Leu Asn Ala-
    29 Ser Gln Ile Cys Asp Gly Leu Arg Gly His Leu Met Thr Val Arg Ser
     31 Ser Val Ala Ala Asp Val Ile Ser Leu Leu Leu Asn Gly AspyGly Gly
E--> 32( 65
                                                                                       08
                                   70
    33 Val Gly Arg Arg Leu Trp Ile Gly Leu Gln Leu Pro Pro Cly Cyc
    35 Gly Asp Pro Lys Arg Leu Gly Pro Leu Arg Gly Phe Gln Trp Val Thr
                                                                           110
E--> 36
                       100
                                                 105
    37 Gly Asp Asn Asn Thr Ser Tyr Ser Arg Trp Ala Arg Leu Asp Leu Asn
    39 Gly Ala Pro Leu Cys Gly Pro Leu Cys Val Ala Val Ser Ala Ala Glu
           ( 130
    41 Ala Thr Val Pro Ser Glu Pro Ile Trp Glu Glu Gln Gln Cys Glu Val
E--> 42(145
                                 150
                                                                                    160
    43 Lys Ala Asp Gly Phe Leu Cys Glu Phe His Phe Pro Ala Thr Cys Arg
    45 Pro Leu Ala Val Glu Pro Gly Ala Ala Ala Ala Val Ser Ile Thr
```

self.2

RAW SEQUENCE LISTING DATE: 07/23/2004
PATENT APPLICATION: US/10/501,671 TIME: 15:23:45

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07232004\J501671.raw

Output Set: N:\CRF4\07232004\J501671.raw											
	190 Same										
E> 46 180 185	190 Jane										
47 Tyr Gly Thr Pro Phe. Ala Ala Arg Gly Ala Asp Phe Gln Ala Leu Pro											
E> 48 195 200 205	$^{\prime}$										
49 Val Gly Ser Ser Ala Ala Val Ala Pro Leu Gly Leu Gln Leu Met Cys											
E> 50 210 215 220											
51 Thr Ala Pro Pro Gly Ala Val Gln Gly His Trp Ala Arg Glu Ala Pro	0.10										
E> 52 225 230 235	240										
53 Gly Ala Trp Asp Cys Ser Val Glu Asn Gly Gly Cys Glu His Ala Cys											
E> 54 245 250	255										
55 Asn Ala Ile Pro Gly Ala Pro Arg Cys Gln Cys Pro Ala Gly Ala Ala											
E> 56 260 265	270										
57 Leu Gln Ala Asp Gly Arg Ser Cys Thr Ala Ser Ala Thr Gln Ser Cys	_										
E> 58 275 280 285	;										
59 Asn Asp Leu Cys Glu His Phe Cys Val Pro Asn Pro Asp Gln Pro Gly											
E> 60 290 295 300											
61 Ser Tyr Ser Cys Met Cys Glu Thr Gly Tyr Arg Leu Ala Ala Asp Gln											
E> 62 305 310 315	320										
63 His Arg Cys Glu Asp Val Asp Asp Cys Ile Leu Glu Pro Ser Pro Cys											
E> 64 325 330	335										
65 Pro Gln Arg Cys Val Asn Thr Gln Gly Gly Phe Glu Cys His Cys Tyr	252										
E> 66 340 345	350										
67 Pro Asn Tyr Asp Leu Val Asp Gly Glu Cys Val Glu Pro Val Asp Pro	_										
E> 68 355 360 365	;										
69 Cys Phe Arg Ala Asn Cys Glu Tyr Gln Cys Gln Pro Leu Asn Gln Thr											
E> 70 370 375 380											
71 Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro Ile Pro His Glu	400										
E> 72 385 390 395	400										
73 Pro His Arg Cys Gln Met Phe Cys Asn Gln Thr Ala Cys Pro Ala Asp E> 74 405 410	415										
75 Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro Glu Gly Tyr Ile	415										
E> 76 420 425	420										
	430										
77 Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu Cys Glu Asn Gly E> 78 435 440 445	•										
E> 78 435 440 445 79 Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly Thr Phe Glu Cys	,										
E> 80 450 455 460											
81 Ile Cys Gly Pro Asp Ser Ala Leu Val Arg His Ile Gly Thr Asp Cys											
E> 82 465 470 475	480										
83 Asp Ser Gly Lys Val Asp Gly Gly Asp Ser Gly Ser Gly Glu Pro Pro	400										
E> 84 485 490	495										
85 Pro Ser Pro Thr Pro Gly Ser Thr Leu Thr Pro Pro Ala Val Gly Leu	495										
E> 86 500 505	510										
87 Val His Ser Gly	510										
E> 88 515											
90 <210> SEQ ID NO: 2											
90 <210> SEQ ID NO: 2 91 <211> LENGTH: 1548 /547 (ρ.3)											
92 <212> TYPE: DNA											
93 <213> ORGANISM: Artificial sequence											
95 <220> FEATURE:											
96 <223> OTHER INFORMATION: Partial base sequence of human-originat	ed coluble										
70 (22) OTHER INFORMATION. FAILTAI DASE SEQUENCE OF INUMATION OF THE PROPERTY	er soluble										

RAW SEQUENCE LISTING PATENT APPLICATION: US/10/501,671

DATE: 07/23/2004 TIME: 15:23:45

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07232004\J501671.raw

```
thrombomodulin gene
     99 <400> SEQUENCE: 2
     100 atgettgggg teetggteet tggegegetg geeetggeeg geetggggtt eeeegeaeee
                                                                               60
     101 gcagagccgc agccgggtgg cagccagtgc gtcgagcacg actgcttcgc gctctacccg
     102 ggccccgcga ccttcctcaa tgccagtcag atctgcgacg gactgcgggg ccacctaatg
                                                                              180
     103 acagtgeget ceteggtgge tgeegatgte attteettge taetgaaegg egaeggegge
                                                                              240
     104 gttggccgcc ggcgcctctg gatcggcctg cagctgccac ccggctgcgg cgaccccaag
                                                                              300
     105 cgcctcgggc ccctgcgcgg cttccagtgg gttacgggag acaacaacac cagctatagc
                                                                              360
     106 aggtgggcac ggctcgacct caatggggct cccctctgcg gcccgttgtg cgtcgctgtc
                                                                              420
     107 teegetgetg aggecactgt geecagegag eegatetggg aggageagea gtgegaagtg
                                                                              480
     108 aaggeegatg getteetetg egagtteeac tteecageea eetgeaggee aetggetgtg
                                                                              540
     109 gagcccggcg ccgcggctgc cgccgtctcg atcacctacg gcaccccgtt cgcggcccgc
                                                                              600
     110 ggageggaet tecaggeget geeggtggge ageteegeeg eggtggetee eeteggetta
                                                                              660
     111 cagetaatgt geacegegee geeeggageg gteeagggge actgggeeag ggaggegeeg
                                                                              720
     112 ggcgcttggg actgcagcgt ggagaacggc ggctgcgagc acgcgtgcaa tgcgatccct
                                                                              780
     113 ggggetecce getgecagtg eccageegge geegeeetge aggeagaegg gegeteetge
     114 accgcatccg cgacgcagtc ctgcaacgac ctctgcgagc acttctgcgt tcccaacccc
     115 gaccageegg geteetacte gtgeatgtge gagaeegget aceggetgge ggeegaeeaa
     116 caccggtgcg aggacgtgga tgactgcata ctggagccca gtccgtgtcc gcagcgctgt 1020
     117 gtcaacacac agggtggctt cgagtgccac tgctacccta actacgacct ggtggacggc 1080
     118 gagtgtgtgg agcccgtgga cccgtgcttc agagccaact gcgagtacca gtgccagccc 1140
     119 ctgaaccaaa ctagctacct ctgcgtctgc gccgagggct tcgcgcccat tccccacgag 1200
     120 ccgcacaggt gccagatgtt ttgcaaccag actgcctgtc cagccgactg cgaccccaac 1260
     121 acccaggeta getgtgagtg ccctgaagge tacateetgg acgaeggttt catetgeacg 1320
     122 gacategaeg agtgegaaaa eggeggette tgeteegggg tgtgeeacaa cet<u>eece</u>ggt 1380
E--> 123 accttegagt gcatctgcgg gcccgactcg gcccttgtcc gccacattgg caccgac (1)1440/439
E--> 124 gactccggca aggtggacgg tggcgacagc ggctctggcg agcccccgcc cagcccgacg 1500/499
E--> 125 cccggetcca cettgaetee teeggeegtg gggetegtge atteggge
     127 <210> SEQ ID NO: 3
     128 <211> LENGTH: 132
                                                          This is a 19 positions, group of positions,
     129 <212> TYPE: PRT
     130 <213> ORGANISM: Artificial sequence
     132 <220> FEATURE:
     133 <223> OTHER INFORMATION: Partial amino acid sequence of human-originated soluble
               thrombomodulin
     134
E--> 136 <400> SEQUENCE: (8) 3 - change to
     137 Met Leu Gly Val Leu Val Leu Gly Ala Leu Ala Leu Ala Gly Leu Gly
E--> 138
                               5
     139 Phe Pro Asp Pro Cys Phe Arg Ala Asn Cys Glu Tyx Gln Cys Gln Pro
     141 Leu Asn Glp Thr Ser Tyr Leu Cys Val Cys Ala Glu Gly Phe Ala Pro
E--> 142
                                               40
     143 Ile Pro His Glu Pro His Arg Cys Gln Met Phe Cys Asn Gln Thr-Ala
             ( 50
E--> 144
                                         55
     145 Cys Pro Ala Asp Cys Asp Pro Asn Thr Gln Ala Ser Cys Glu Cys Pro
E--> 146 (65
                                                                                         80
     147 Glu Gly Tyr Ile Leu Asp Asp Gly Phe Ile Cys Thr Asp Ile Asp Glu
E--> 148
     149 Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly
```

misaligned amero acid humbers
sel P.4

DATE: 07/23/2004

PATENT APPLICATION: US/10/501,671 TIME: 15:23:45 misebyred 110 hunber Input Set : A:\PTO.FG.txt Output Set: N:\CRF4\07232004\J501671.raw E--> 150 105 151 Thr Phe Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Val Arg His Ile 115 120 153 Gly Thr Asp Cys E--> 154 130 174 <210> SEQ ID NO: 5 175 <211> LENGTH: 516 176 <212> TYPE: PRT 177 <213> ORGANISM: Artificial sequence 179 <220> FEATURE: 180 <223> OTHER INFORMATION: Partial amino acid sequence of human-originated soluble thrombomodulin 183 <400> SEQUENCE: 5 184 Met Leu Gly Val Leu Val Leu Gly Ala Leu Ala Leu Ala Gly Leu Gly E--> 185 186 Phe Pro Ala Pro Ala Glu Pro Gln Pro Gly Gly Ser Gln Cys Val Glu 20 188 His Asp Cys Phe Ala Leu Tyr Pro Gly Pro Ala Thr Phe Leu Asn Ala 35 40 190 Ser Glm Ile Cys Asp Gly Leu Arg Gly His Leu Met Thr Val Arg Ser) 50 192 Ser Val Ala Ala Asp Val Ile Ser Leu Leu Leu Asn Gly Asp Gly Gly E--> 193(65 70 80 194 Val Gly Arg Arg Leu Trp Ile Gly Leu Gln Leu Pro Pro Gly Cys 85 95 196 Gly Asp Pro Lys Arg Leu Gly Pro Leu Arg Gly Phe Gln Trp Val Thr 100 105 110 E--> 197 198 Gly Asp Asn Asn Thr Ser Tyr Ser Arg Trp Ala Arg Leu Asp Leu Asn 200 Gly Ala Pro Leu Cys Gly Pro Leu Cys Val Ala Val Ser Ala Ala Glu E--> 201 (130 135 202/Ala Thr Val Pro Ser Glu Pro Ile Trp Glu Glu Gln Gln Cys Glu Val E--> 203 145 _____150 160 204 Lys Ala Asp Gly Phe Leu Cys Glu Phe His Phe Pro Ala Thr Cys Arg 165 170 175 206 Pro Leu Ala Val Glu Pro Gly Ala Ala Ala Ala Ala Val Ser Ile Thr E--> 207 180 185 190 208 Tyr Gly Thr Pro Phe Ala Ala Arg Gly Ala Asp Phe Gln Ala Leu Pro-(195 200 210 Val Gly Ser Ser Ala Ala Val Ala Pro Leu Gly Leu Gln Leu Met Cys-212 Thr Ala Pro Pro Gly Ala Val Gln Gly His Trp Ala Arg Glu Ala Pro E--> 213 225 240 230 214 Gly Ala Trp Asp Cys Ser Val Glu Asn Gly Gly Cys Glu His Ala Cys **245** 255 E--> 215 216 Asn Ala Ile Pro Gly Ala Pro Arg Cys Gln Cys Pro Ala Gly Ala Ala

<u> 265</u>

280

218 Leu Gln Ala Asp Gly Arg Ser Cys Thr Ala Ser Ala Thr Gln Ser Cys

RAW SEQUENCE LISTING

P.5

270

E--> 219

275

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/501,671

DATE: 07/23/2004 TIME: 15:23:45

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07232004\J501671.raw

					Out	out i	set:	W:/(LKF4	(0/23	2009	1000	170/7	L. raw	•			A -	. 1
		•	3	7	~	a 1	772 -	Dl	a	77-7	D	7	D	2	~1 ~	Dwo	C1	Sa	ne
	220	Asn	Asp	ьeu	Cys	GIU	HIS	Pne	Cys,	vaı	Pro	ASI	Pro	Asp	GIII	500	Gry	^	
E>	221	000	Z 3 (, ,	Crea	Mot	C	~1	mb~	293 Cl	Па гас	7~~	T 011	71-	712	200	Gln	لار	/UU -
	222	205	ıyı	ser	Cys	Met	Cys	31(7 111T	GIY	ıyr	Arg	ьец	Ala	15	тэр	GIII		320
E>			7. ~~	Crea	C1,,	7 an	1707			Crra	т1.	T 011	C1.,			Dro	Cvc		320
.		птъ	Arg	Cys	GIU	Asp	325		Asp	Cys	TIE	ьеи	33		261	PIO	Cys		335
E>		Dro	Cln	7~~	Cara	v-1			Cln	C111	Clar	Dho			Uic	Cve	Tur		333
		PIO	GIII	Arg	Cys	340	ASII	1111	GIII	Gly	Gry			Cys	UTP	Cys	ığı	350	
E>		Dwo	7 00	Ф	7.00		17-1	7 02	C1	C1.,	Cara	345		Dro	1723	λαn	Pro	350	
		PIO	ASII	-	Аър 55	теп		Asp	GIY	Glu	360	vai	GIU	PIO	vaı	лър	365		
E>		Crea	Dho		-	Λan	Cva	C1.,	Ттт	Gln		Cln	D~o	Lou	7 cn	Gl n			
B>		Cys	370	_	Ala	ASII	Cys	GIU	-	375	Cys	GIII	PIO	пеп		380	1111		
B>		C0~			Crrc	17a l	Cva	717		Gly	Dho	71-	Dro	T10			Glu		
			ıyı	ьeu	Cys	vai	Cys	390		GIY	Pile	AIA	PIO	35		птъ	Giu		400
E>			Uic	7~~	Crra	C1 n	Mot		-	Asn	~1n	Thr	- וג		-	ת ה	N G P		400
		PIO	птр	Arg	Cys	GIII	405		Cys	ASII	GIII	TIII		LO LO	PIO	АТа	Азр		415
E>		Crra	7 ~~	Dro	7 02	Th~			cor	Cys	C1,,	Caro			Gl ₃₂	Тиг	Tla		413
.		Cys	Asp	PIO	ASII	420	GIII	Ата	ser	Cys	GIU	425		GIU	Gry	ıyı	116	430	
E>		LOU	7 cn	7 cn	C1 11		Tla	Cvc	Thr	Asp	Tla			Cvc	Glu	λen	Glv	430	
7 7		ьец	Asp	_	-	PHE.	TIE	Cys	1111	Asp	440	Asp	GIU	Cys	GIU	ASII			
E>		a1	Dha		35	~1	1707	O	111.0	Asn		Dwo	~1··	Thr	Dho	C1	445		
		GTÀ		_	ser	Gry	vai	Cys			ьец	PIO	GIA	1111	Pile		Cys		
E>		- 1-	450		D	7	0	77.		455	7	TT-1	т1.	~1	mh =	460	C		
			Cys	GIY	PIO	Asp	ser			Ala	Arg	HIS	тте	_		Asp	Cys		400
E>			0	01	T	***	7	470	-	7	C	~1	C	47	_	Dwa	Dwo		480
		Asp	ser	GIY	ьуѕ	vai			GIY	Asp	ser	GIY	-		GIU	PIO	PIO		405
E>		Dwo	Com	Dwo	mb	Dwa	48!		mb w	T 011	mh w	Dwo		90 212	Wa I	C1	Tou		495
		PIO	ser	PIO	THI		GIY	ser	IIIL	Leu	TIIL			AIa	vai	GLY	пеп	E10	
E>		77_ T	***	0	01	500						505	•					510	
		vai	His		_														
E>	_	-21	0> SI	51 FO TI		. 7													
						_													
			1> LE 2> TY			34													
						7 mt	ifia	ial (a com 1	anca									
1.7 .						ALC.	ific:	iai i	seque	ence									
W>						יעאם כי	PT ON	. Da	~+i~	1	ino -		a0a	10ng	. of	huma	n-ori	icinate	ad golubla
		<22.	_	aromi				. Pa.	LUIA.	ı aııı.	LIIO 6	aciu	sequ	rence	: 01	munic	111-OL.	iginace	ed soluble
	294	-40					.1												
			0> SI				บรา	Lou	Clv	Ala	T 011	۸la	Leu	λla	Gl ₃₂	Lau	-G-7-77		
P .		_	ьеu	GIY	vai	ьец	vai	ьец	Gry	АІа	пеп	на	пеп	10	GIY	пе п-	GIY		15
E>		Dho.	Dwo	7 ~~	Dwo	Crea	Dho	7.20	712	Asn	Circ	<u> </u>	There		Circ	<u> </u>	DEC		
		Pne	PIO	ASP	PIO	20	Pne	Arg	Ala	ASII	Cys			GIII	Cys	GIII	PIO	30)
E>		T 011	7	~1 ~	The		TT	T ou	Crea	7707	Circ	25		<u></u>	Dho	X 1 3	Dec		
		ьeu	ASII	GIII		ser	TAT	ьeu	Cys	Val	_	Ата	GIU	GIY	Pile	Ala	41	. –	
E>		T1.	Dros	114 ~	35	Droc	U - ~	7	Carr	Gln	40	Dha	Cira	7.55	C1=	Th-			
		тте			GIU	Pro	HIS	arg			Met	Pne	Cys	ASI	GIII		Ala		
E>		C	50		7	Cree	7	Desir		55	<u> </u>	77-		<u></u>	<u> </u>	60	D20-	-	
_		/ -		АТА	Asp	cys	Asp			Thr	GIN	Ата	ser	cys		cys	PIO		
E>				m	T7 -	T 6::	7	7		Db -	T7 -	Comm	mb	7	75	7	-a1		80
	307	GLU	GTA	Tyr	тте	ьeu	Asp	Asp	GTA	Phe	тте	cys	ınr	Asp	тте	Asp	GIU		
																	_		

misaligied anero acid humbers
P. 6

RAW SEQUENCE LISTING

DATE: 07/23/2004

PATENT APPLICATION: US/10/501,671

TIME: 15:23:45

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07232004\J501671.raw

E--> 308 309 Cys Glu Asn Gly Gly Phe Cys Ser Gly Val Cys His Asn Leu Pro Gly 110 100 311 Thr Phe Glu Cys Ile Cys Gly Pro Asp Ser Ala Leu Ala Arg His Ile 120 E--> 312 115 313 Gly Thr Asp Cys E--> 314 130

334 <210> SEQ ID NO: 9

335 <211> LENGTH: 21 336 <212> TYPE: DNA

337 <213> ORGANISM: Artificial sequence

339 <220> FEATURE:

340 <223> OTHER INFORMATION: Synthetic DNA for mutation

342 <400> SEQUENCE: 9

343 aatgtggcgg gcaagggccg a

21

E--> 349(1/12)

RAW SEQUENCE LISTING ERROR SUMMARY PATENT APPLICATION: US/10/501,671

DATE: 07/23/2004 TIME: 15:23:46

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07232004\J501671.raw

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 32 Seq#:3; Line(s) 146 Seq#:4; Line(s) 172

Seq#:7; Line(s) 306

Seq#:8; Line(s) 332

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/501,671

DATE: 07/23/2004 TIME: 15:23:46

Input Set : A:\PTO.FG.txt

Output Set: N:\CRF4\07232004\J501671.raw

L:4 M:283 W: Missing Blank Line separator, <120> field identifier L:8 M:270 C: Current Application Number differs, Replaced Current Application No L:8 M:271 C: Current Filing Date differs, Replaced Current Filing Date L:24 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:1 M:332 Repeated in SeqNo=1 L:123 M:254 E: No. of Bases conflict, LENGTH:Input:1440 Counted:1439 SEQ:2 L:123 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:1 M:254 Repeated in SeqNo=2 L:125 M:252 E: No. of Seq. differs, <211> LENGTH:Input:1548 Found:1547 SEQ:2 L:136 M:212 E: (34) Invalid or duplicate Sequence ID Number, SEQUENCE ID NOS:3 differs:8 L:138 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:8 / M:332 Repeated in SeqNo=3 L:185 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:5 M:332 Repeated in SeqNo=5 L:292 M:283 W: Missing Blank Line separator, <220> field identifier L:298 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:7 / M:332 Repeated in SeqNo=7

L:349 M:254 E: No. of Bases conflict, LENGTH:Input:12 Counted:22 SEQ:9 L:349 M:320 E: (1) Wrong Nucleic Acid Designator, NUMBER OF INVALID KEYS:2 L:349 M:252 E: No. of Seq. differs, <211> LENGTH:Input:21 Found:22 SEQ:9